US FDA advisers back Replimune skin cancer drug trial data
- Posted on July 30, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
US FDA advisers back Replimune skin cancer drug trial data
By Puyaan Singh July 30 (Reuters) - The U.S. Food and Drug Administration's panel of outside advisers on Thursday voted to back results from a trial studying Replimune's drug for a type of skin cancer. The FDA had declined to approve the drug, RP1, for a second time in April, citing reliance on a study without a control group, and sought more data demonstrating adequate evidence of the drug's
